Edition:
India

Enanta Pharmaceuticals Inc (ENTA.OQ)

ENTA.OQ on NASDAQ Stock Exchange Global Select Market

48.52USD
17 Nov 2017
Change (% chg)

$0.40 (+0.83%)
Prev Close
$48.12
Open
$47.91
Day's High
$49.34
Day's Low
$47.77
Volume
72,491
Avg. Vol
71,699
52-wk High
$50.89
52-wk Low
$25.92

Latest Key Developments (Source: Significant Developments)

Enanta Pharmaceuticals announces AbbVie's investigational HCV regimen receives U.S. FDA breakthrough therapy designation
Friday, 30 Sep 2016 

Enanta Pharmaceuticals Inc : Enanta Pharmaceuticals announces AbbVie's investigational HCV regimen receives U.S. FDA breakthrough therapy designation .According to FDA,BTD is intended to expedite development,review of an investigational therapy for serious condition.  Full Article

Enanta Pharmaceuticals Q3 loss per share $0.06
Tuesday, 9 Aug 2016 

Enanta Pharmaceuticals Inc : Enanta Pharmaceuticals reports financial results for its fiscal third quarter ended June 30, 2016 . Q3 loss per share $0.06 . Q3 earnings per share view $-0.10 -- Thomson Reuters I/B/E/S . Q3 revenue $14 million versus I/B/E/S view $13 million .U.S. FDA granted marketing approval for Abbvie's Viekira XR((TM))for treatment of genotype 1 hepatitis c virus.  Full Article

Abbvie says CHMP grants positive opinion for shorter treatment duration with VIEKIRAX
Monday, 25 Jul 2016 

Abbvie Inc : CHMP grants positive opinion for shorter treatment duration with Abbvie's VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) for patients with genotype 4 chronic hepatitis C with compensated cirrhosis (child-pugh a) .Says VIEKIRAX with RBV is currently approved in European Union for GT4 patients with compensated cirrhosis for 24 weeks.  Full Article

Enanta pharmaceuticals Q2 loss per share $0.09
Tuesday, 10 May 2016 

Enanta Pharmaceuticals Inc : Enanta pharmaceuticals reports financial results for its fiscal second quarter ended march 31, 2016 . Q2 loss per share $0.09 . Q2 earnings per share view $0.10 -- Thomson Reuters I/B/E/S . Q2 revenue $13 million versus $57.4 million .Q2 revenue view $16.8 million -- Thomson Reuters I/B/E/S.  Full Article

BRIEF-Enanta Pharmaceuticals reports positive phase 1 A/B clinical results for its lead fxr agonist

* Enanta Pharmaceuticals announces positive phase 1 a/b clinical results for its lead fxr agonist, edp-305